

Synthesis of Strained 1,3-Diene Macrocycles via Copper-Mediated Castro-Stephens Coupling/Alkyne Reduction Tandem Reactions

Wei Li,[†] Christopher M. Schneider,[‡] and Gunda I. Georg*,[†]

Supporting Information

ABSTRACT: A copper-mediated macrocyclization involving the reaction of a vinyl iodide and a terminal alkyne followed by an in situ reduction of the enyne intermediate is reported. The reaction generates a conjugated Z-double bond within a strained medium-size lactone, lactam, or ether macrocycle. A variety of macrocyclic

compounds bearing different ring sizes and functionalities were synthesized. A complementary stepwise procedure was also developed for less strained ring systems.

I ighly functionalized macrocycles are prevalent structural I features in natural products and are present in more than 100 marketed drugs. We are particularly interested in macrocycles possessing conjugated E₁Z-polyene units within the ring since this motif is present in a number of natural products with diverse and potent bioactivities such as latrunculin A, oximidine II, lactimidomycin, and radicicol (Figure 1).²

Figure 1. Selected examples of polyunsaturated macrocyclic natural products.

Most reported total syntheses of these natural products rely on variants of ring-closing metathesis (RCM) reactions, which exhibited low efficiency for highly strained ring systems such as oximidine II^{3c} and could potentially generate E/Zisomers and ring contraction products.3f,4 A palladiumcatalyzed Suzuki cross-coupling reaction was also employed for the synthesis of oximidine II,5 but the yield for the macrocyclization was similar to those achieved with RCM

reactions. A sequential RCM/intramolecular palladium-catalyzed cross-coupling reaction between an alkenyl iodide and a siloxane also provided access to an oximidine-like macrocyclic structure and related analogues in good yields.⁶ For the synthesis of lactimidomycin, the E,Z-configuration of the 1,3diene was established using a RCM reaction; however, a silyl directing group was needed for regio- and stereocontrol.3 Despite these successful total syntheses, methods to prepare conjugated polyene macrocycles are underexplored, and new efficient methods that are tolerant of diverse functional groups would be important to further explore these types of structures for biomedical applications.

We pursued an alternative approach to this structural motif via a two-step ene-yene macrocyclization⁷/alkyne reduction sequence en route to the total synthesis of oximidine II (Scheme 1). Initial attempts were disappointing. The highly strained cyclic dienyne intermediate was obtained in very low yield, and the double bond underwent E-Z isomerization to release ring strain.8 Further investigations revealed that the ene-yne coupling reaction performed in the presence of the

Scheme 1. Ene-Yne Coupling/Reduction Approach in the Total Synthesis of Oximidine II

Received: July 1, 2015 Published: July 15, 2015

Department of Chemistry, Department of Medicinal Chemistry, and the Institute for Therapeutics Discovery and Development, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States


[‡]Department of Medicinal Chemistry, University of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045, United States

Organic Letters Letter

reducing reagent sodium formate allowed the in situ reduction of the dienyne to afford the desired triene macrocycle in a single step. The 67% yield compared favorably to the 40–50% yields reported for the ring-closing steps in the two previous total syntheses. Encouraged by this success, we decided to explore this coupling/reduction tandem transformation as a general method for the construction of conjugated polyunsaturated macrocycles.

For optimization studies, we initially examined the coupling/reduction tandem reaction with vinyl iodide 1a (Table 1) under conditions similar to those reported for the

Table 1. Optimization of the Reaction Conditions^a



| entry | temp (°C) | solvent | ligand | yield ^b (%) | ratio $(2a/3a)^c$ |
|-----------------|--------------|---------|---------------|---------------------------|-------------------|
| 1 | 120 | DMF | PPh_3 | 34 | 20:1 |
| 2 | 100 | DMF | PPh_3 | 0 | N/A |
| 3 | 140 | DMF | PPh_3 | 19 | 6:1 |
| 4 | 120 | DMSO | PPh_3 | 31 | 20:1 |
| 5 | 120 | toluene | PPh_3 | 0 | N/A |
| 6 | 120 | dioxane | PPh_3 | 0 | N/A |
| 7 | 120 | DMF | P^tBu_3 | 49 | 20:1 |
| 8 | 120 | DMF | $P(OEt)_3$ | 53 | 18:1 |
| 9^d | 120 | DMF | PPh_3 | 64 | 90:1 |
| 10 | 120 | DMF | dppe | 73 | 11:1 |
| 11 | 120 | DMF | rac-BINAP | 72 | 25:1 |
| 12 | 120 | DMF | (R)-phanephos | 71 | 44:1 |
| 13^e | 120 | DMF | (R)-phanephos | 73 | 44:1 |
| 14 ^f | 120 | DMF | (R)-phanephos | N/A | 28:1 |
| 15 | 120 | DMF | L-proline | 30 | 4:1 |
| 16 | 120 | DMF | DMEDA | 39 | 20:1 |

^aReaction conditions unless otherwise specified: **1a** (0.005 M), $Cu(OAc)_2$ (0.33 equiv), ligand (P/Cu = 3), HCO_2Na (4 equiv), K_2CO_3 (1.5 equiv) under N_2 for 2 h. ^bIsolated yield. ^cCalculated from ¹H NMR. ^dCu(OAc)₂ (1 equiv) and PPh₃ (1 equiv) were used. ^eCu(OAc)₂ (0.2 equiv) and phanephos (0.3 equiv) were used. ^fCu(OAc)₂ (0.1 equiv), phanephos (0.15 equiv) and reaction time (4 h); 70% conversion. Dppe = 1,2-bis(diphenylphosphinoethane; BINAP = bis(diphenyl-phosphino)-1,1'-binaphthalene; phanephos = 4,12-bis(diphenylphosphino)[2.2]paracyclophane; DMEDA = N_1N' -dimethylethylenediamine.

total synthesis of oximidine II (HCO2Na (4 equiv), K2CO3, (1.5 equiv), Cu(OAc)₂ (0.33 equiv), and PPh₃ (1 equiv) at 120 °C in DMF for 2 h). We employed Cu(OAc)₂ as the metal source instead of the previously reported CuI because we observed better reproducibility of the reaction on large scale with Cu(OAc)₂. When these conditions were employed, vinyl iodide 1a furnished the expected 12membered E,Z-diene lactone 2a in a modest 34% yield along with the undesired acylic product 3a (entry 1). At 100 °C (Table 1, entry 2), no conversion was observed, while at 140 °C (Table 1, entry 3) both yield and selectivity decreased. The reaction performed best at 120 °C (entries 1 and 4). Next, DMF was identified as the optimal solvent (entries 4-6). Less polar solvents (entries 5 and 6) were inefficient. Using other monodentate phosphorus ligands (entries 7 and 8) slightly improved the yields. Stoichiometric amounts of Cu(OAc)₂ and 3 equiv of PPh₃ facilitated the

reaction significantly (entry 9). Finally, we were pleased to find that high yields of over 70% could be achieved with bidentate ligands under catalytic conditions (HCO₂Na (4 equiv), K_2CO_3 , (1.5 equiv), $Cu(OAc)_2$ (0.33 equiv), and bidentate ligand (0.5 equiv) at 120 °C in DMF for 2 h, entries 10—12). Among them, phanephos afforded the best selectivity for diene 2a, and the efficiency was not diminished under lower catalyst loading (0.2 equiv of $Cu(OAc)_2$ 0.3 equiv of phanephos, entry 13). Further lowering the catalyst loading (0.1 equiv of $Cu(OAc)_2$ 0.15 equiv of phanephos, entry 14) resulted in incomplete reaction (70% conversion) even after 4 h. N- or O-ligands exhibited inferior reactivities (entries 15 and 16).

We next applied this coupling/reduction tandem reaction to the synthesis of a diverse set of substrates (Table 2). We found that 11- to 13-membered rings 2a, 2b, and 2d with an E,Z-1,3-diene moiety were obtained in good yields (Table 2, entries 1, 2, and 4). A more strained 10-membered homologue 2c was also accessible, albeit only in 26% yield (entry 3). The alkyne reduction step was clearly driven by the release of ring strain from the envne intermediate, which in case of the 13-membered ring analogue (entry 4) was observed after 2 h but converted to 2d after 22-24 h. 14-Membered (entry 5) or larger rings formed the enyne but were not reduced to produce dienes even after prolonged reaction time. A phenylvinyl iodide with an ether linkage (entry 7) worked equally as the ester linkages. An unprotected phenol and a secondary amide (entries 8 and 9) were not well tolerated. In contrast, a protected amide (entry 10) provided the desired lactam 2j in 79% yield. Both vinyl iodide and terminal alkyne coupling partners can be aromatic or aliphatic (entries 11 and 12). Vinyl iodide doublebond isomerization was observed for substrate 11 (entry 12A and Scheme 2), which furnished an inseparable mixture (11:1) of 21 and enyne 4. When dppe was used as the ligand, 21 was obtained in 82% as the sole product (entry 12 B). Z,Z-Diene macrocycles were difficult to access with this method since the Z-enyne intermediate is much less strained than its E-counterpart, and thus, the alkyne reduction did not take place (entry 13). When the ring system was strained enough to afford the desired diene product 2n in 30% yield (entry 14), significant amounts of the dimer 5 (34%) were formed concomitantly (Scheme 2). In the majority of the above examples, the undesired deiodinated product 3 was negligible. For those substrates that produced a significant quantity of compound 3, the use of stoichiometric amounts of copper and ligand could completely suppress the side reaction (entries 4 and 6).

Ring systems that were not strained enough to trigger the in situ alkyne reduction afforded macrocyclic enynes. This transformation is worth noting, since the intramolecular ene—yne C–C couplings (Sonogashira or Castro–Stephens) have not been widely applied to macrocyclizations, 8,11 and most of them employed phenyl iodide substrates. In addition, the desired diene macrocycles could be obtained from the enynes through a sequential reduction step (Scheme 3). Thus, the iodides were subjected to the ene—yne coupling conditions in the absence of HCO2Na, and the crude enyne was then treated with in situ formed Cu–H. The 14-membered macrocycle 2e and 17-membered macrocycle 2p were synthesized using these conditions. Double-bond isomerization as seen in Pd-catalyzed transhydrogenation of enynes was not detected herein.

Organic Letters Letter

Table 2. Reaction Scope

6

7

"Reaction conditions unless otherwise specified: 1 (0.005 M), HCO₂Na (4 equiv), K₂CO₃ (1.5 equiv) under N₂; (A) Cu(OAc)₂ (0.2 equiv), phanephos (0.3 equiv); (B) Cu(OAc)₂ (0.33 equiv), BINAP (0.5 equiv); (C) Cu(OAc)₂ (1 equiv), PPh₃ (3 equiv); (D) Cu(OAc)₂ (0.33 equiv), dppe (0.5 equiv). Reaction times were not fully optimized. ^bIsolated yield. ^cCalculated from ¹H NMR. ^dCu(OAc)₂ (0.1 equiv), phanephos (0.15 equiv) were used. ^eCu(OAc)₂ (0.33 equiv), phanephos (0.33 equiv) were used. ^fOnly enyne was isolated. ^gDecomposed. ^hCombined yield of inseparable mixture of diene 2l and enyne 4 (ratio 11:1). ⁱ34% of dimerized product 5 was also isolated.

13

Scheme 2. Reactions of Substrates 11 and 1n



A, 2 h

C, 2 h

 A^d , 6 h

60

60

62

5.6:1

2f only

2g only

Scheme 3. Stepwise Coupling/Reduction Synthesis of 14and 17-Membered Macrocycles

In summary, a tandem reaction involving an intramolecular Castro—Stephens coupling and in situ alkyne semireduction has been developed for the construction of macrocycles containing conjugated *E,Z*-diene units. The reaction is ring-strain dependent and particularly efficient for 11–13-

membered rings. The synthesis of larger and thus less strained macrocycles can be realized through a complementary stepwise sequence. This methodology has been previously used in the total synthesis of the natural product oximidine II, and very recently, we have completed a concise formal total synthesis of lactimidomycin employing the improved conditions that we have discussed in this report.¹⁴ Further investigations on applications in natural product synthesis are in progress.

A, 3 h

A, 5 h

Of

30

N/A

N/A

ASSOCIATED CONTENT

S Supporting Information

Experimental section, characterization data, and NMR spectra. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.5b01892.

AUTHOR INFORMATION

Corresponding Author

*E-mail: georg@umn.edu.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by the University of Minnesota through the Vince and McKnight Endowed Chairs.

Organic Letters Letter

REFERENCES

- (1) (a) Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. Nat. Rev. Drug Discovery 2008, 7, 608. (b) Harvey, A. L. Drug Discovery Today 2008, 13, 894. (c) Mallinson, J.; Collins, I. Future Med. Chem. 2012, 4, 1409. (d) Butler, M. S.; Robertson, A. A.; Cooper, M. A. Nat. Prod. Rep. 2014, 31, 1612. (e) Marsault, E.; Peterson, M. L. J. Med. Chem. 2011, 54, 1961.
- (2) (a) Neeman, I.; Fishelson, L.; Kashman, Y. Mar. Biol. 1975, 30, 293. (b) Spector, I.; Shochet, N. R.; Kashman, Y.; Groweiss, A. Science 1983, 219, 493. (c) Groweiss, A.; Shmueli, U.; Kashman, Y. J. Org. Chem. 1983, 48, 3512. (d) Kim, J. W.; Shin-Ya, K.; Furihata, K.; Hayakawa, Y.; Seto, H. J. Org. Chem. 1999, 64, 153. (e) Sugawara, K.; Nishiyama, Y.; Toda, S.; Komiyama, N.; Hatori, M.; Moriyama, T.; Sawada, Y.; Kamei, H.; Konishi, M.; Oki, T. J. Antibiot. 1992, 45, 1433. (f) Ju, J.; Seo, J.-W.; Her, Y.; Lim, S.-K.; Shen, B. Org. Lett. 2007, 9, 5183. (g) Delmotte, P.; Delmotte-Plaquée, J. Nature 1953, 171, 344. (h) Mirrington, R. N.; Ritchie, E.; Shoppee, C. W.; Taylor, W. C.; Sternhell, S. Tetrahedron Lett. 1964, 5, 365. (i) McCapra, F.; Scott, A. I.; Delmotte, P.; Delmotte-Plaquée, J.; Bhacca, N. S. Tetrahedron Lett. 1964, 5, 869. (j) Cutler, H. G.; Arrendale, R. F.; Springer, J. P.; Cole, P. D.; Roberts, R. G.; Hanlin, R. T. Agric. Biol. Chem. 1987, 51, 3331.
- (3) (a) Fürstner, A.; Turet, L. Angew. Chem., Int. Ed. 2005, 44, 3462. (b) Fürstner, A.; De Souza, D.; Turet, L.; Fenster, M. D. B.; Parra-Rapado, L.; Wirtz, C.; Mynott, R.; Lehmann, C. W. Chem. Eur. J. 2007, 13, 115. (c) Wang, X.; Porco, J. A., Jr. J. Am. Chem. Soc. 2003, 125, 6040. (d) Wang, X.; Bowman, E. J.; Bowman, B. J.; Porco, J. A., Jr. Angew. Chem., Int. Ed. 2004, 43, 3601. (e) Micoine, K.; Fürstner, A. J. Am. Chem. Soc. 2010, 132, 14064. (f) Gallenkamp, D.; Fürstner, A. J. Am. Chem. Soc. 2011, 133, 9232. (g) Micoine, K.; Persich, P.; Llaveria, J.; Lam, M. H.; Maderna, A.; Loganzo, F.; Fürstner, A. Chem. Eur. J. 2013, 19, 7370. (h) Garbaccio, R. M.; Danishefsky, S. J. Org. Lett. 2000, 2, 3127. (i) Garbaccio, R. M.; Stachel, S. J.; Baeschlin, D. K.; Danishefsky, S. J. J. Am. Chem. Soc. 2001, 123, 10903. (j) Barluenga, S.; Moulin, E.; Lopez, P.; Winssinger, N. Chem. Eur. J. 2005, 11, 4935.
- (4) (a) Wagner, J.; Martin Cabrejas, L. M.; Grossmith, C. E.; Papageorgiou, C.; Senia, F.; Wagner, D.; France, J.; Nolan, S. P. J. Org. Chem. 2000, 65, 9255. (b) Paquette, L. A.; Basu, K.; Eppich, J. C.; Hofferberth, J. E. Helv. Chim. Acta 2002, 85, 3033. (c) Biswas, K.; Lin, H.; Njardarson, J. T.; Chappell, M. D.; Chou, T.-C.; Guan, Y.; Tong, W. P.; He, L.; Horwitz, S. B.; Danishefsky, S. J. J. Am. Chem. Soc. 2002, 124, 9825. (d) Evano, G.; Schaus, J. V.; Panek, J. S. Org. Lett. 2004, 6, 525. (e) Lu, K.; Huang, M.; Xiang, Z.; Liu, Y.; Chen, J.; Yang, Z. Org. Lett. 2006, 8, 1193. (f) Li, P.; Li, J.; Arikan, F.; Ahlbrecht, W.; Dieckmann, M.; Menche, D. J. Org. Chem. 2010, 75, 2429. (g) Rössle, M.; Del Valle, D. J.; Krische, M. J. Org. Lett. 2011, 13, 1482.
- (5) Molander, G. A.; Dehmel, F. J. Am. Chem. Soc. 2004, 126, 10313.
- (6) Denmark, S. E.; Muhuhi, J. M. J. Am. Chem. Soc. 2010, 132, 11768.
- (7) (a) Evano, G.; Blanchard, N.; Toumi, M. Chem. Rev. 2008, 108, 3054. (b) Stephens, R. D.; Castro, C. E. J. Org. Chem. 1963, 28, 3313. (c) Okuro, K.; Furuune, M.; Enna, M.; Miura, M.; Nomura, M. J. Org. Chem. 1993, 58, 4716.
- (8) (a) Haack, T.; Kurtkaya, S.; Snyder, J. P.; Georg, G. I. *Org. Lett.* **2003**, *S*, 5019. (b) Similar synthetic study by another group: Coleman, R. S.; Garg, R. *Org. Lett.* **2001**, *3*, 3487.
- (9) Schneider, C. M.; Khownium, K.; Li, W.; Spletstoser, J. T.; Haack, T.; Georg, G. I. Angew. Chem., Int. Ed. 2011, 50, 7855.
- (10) Schneider, C. M. Ph.D. Thesis, The University of Kansas, Lawrence, KS, 2009.
- (11) Examples of macrocyclic ene—yne couplings: (a) Spivey, A. C.; McKendrick, J.; Srikaran, R. J. Org. Chem. 2003, 68, 1843. (b) Koyama, Y.; Lear, M. J.; Yoshimura, F.; Ohashi, I.; Mashimo, T.; Hirama, M. Org. Lett. 2005, 7, 267. (c) Balraju, V.; Reddy, D. S.; Periasamy, M.; Iqbal, J. J. Org. Chem. 2005, 70, 9626. (d) Krauss, J.; Unterreitmeier, D.; Neudert, C.; Bracher, F. Arch. Pharm. 2005, 338,

- 605. (e) Hussain, A.; Yousuf, S. K.; Kumar, D.; Lambu, M.; Singh, B.; Maity, S.; Mukherjee, D. Adv. Synth. Catal. 2012, 354, 1933. (f) Niu, T.; Sun, M.; Lv, M.; Yi, W.; Cai, C. Org. Biomol. Chem. 2013, 11, 7232. (g) Santandrea, F.; Bédard, A.-C.; Collins, S. K. Org. Lett. 2014, 16, 3892.
- (12) Whittaker, A. M.; Lalic, G. Org. Lett. 2013, 15, 1112.
- (13) Hauwert, P.; Maestri, G.; Sprengers, J. W.; Catellani, M.; Elsevier, C. J. Angew. Chem., Int. Ed. 2008, 47, 3223.
- (14) Li, W.; Georg, G. I. Chem. Commun. 2015, 51, 8634.